Marcella Alsan1, Michael Klompas1. 1. Infectious Diseases Division, Brigham and Women's Hospital (Drs. Alsan and Klompas), and the Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA (Dr. Klompas).
Abstract
OBJECTIVE: To review the clinical significance, management, and control of Acinetobacter infections. METHODS: Literature review. RESULTS: Acinetobacter infections have become a major cause of hospital-acquired infections worldwide. Acinetobacter is noted for its ability to survive for long periods on hospital surfaces and equipment, its predilection to develop resistance to multiple antibiotics, its affinity to cause serious infections in critically ill patients, and many well described outbreaks attributable to contamination of a common source. The crude ICU mortality is approximately 40%. Rigorous antibiotic stewardship and infection control measures are critical to prevent the spread of multidrug-resistant Acinetobacter infections. There is also a pressing need for new therapeutic options. CONCLUSION: Acinetobacter is an emerging pathogen of increasing significance.
OBJECTIVE: To review the clinical significance, management, and control of Acinetobacter infections. METHODS: Literature review. RESULTS:Acinetobacter infections have become a major cause of hospital-acquired infections worldwide. Acinetobacter is noted for its ability to survive for long periods on hospital surfaces and equipment, its predilection to develop resistance to multiple antibiotics, its affinity to cause serious infections in critically illpatients, and many well described outbreaks attributable to contamination of a common source. The crude ICU mortality is approximately 40%. Rigorous antibiotic stewardship and infection control measures are critical to prevent the spread of multidrug-resistant Acinetobacter infections. There is also a pressing need for new therapeutic options. CONCLUSION:Acinetobacter is an emerging pathogen of increasing significance.
Authors: Jian Li; Craig R Rayner; Roger L Nation; Roxanne J Owen; Denis Spelman; Kar Eng Tan; Lisa Liolios Journal: Antimicrob Agents Chemother Date: 2006-09 Impact factor: 5.191
Authors: George H Talbot; John Bradley; John E Edwards; David Gilbert; Michael Scheld; John G Bartlett Journal: Clin Infect Dis Date: 2005-01-25 Impact factor: 9.079
Authors: Matthew E Griffith; Julia M Ceremuga; Michael W Ellis; Charles H Guymon; Duane R Hospenthal; Clinton K Murray Journal: Infect Control Hosp Epidemiol Date: 2006-06-12 Impact factor: 3.254
Authors: Nicholas M Anstey; Bart J Currie; Marilyn Hassell; Didier Palmer; Brian Dwyer; Harald Seifert Journal: J Clin Microbiol Date: 2002-02 Impact factor: 5.948
Authors: J L García-Garmendia; C Ortiz-Leyba; J Garnacho-Montero; F J Jiménez-Jiménez; J Monterrubio-Villar; M Gili-Miner Journal: Crit Care Med Date: 1999-09 Impact factor: 7.598
Authors: Juliana M Coelho; Jane F Turton; Mary E Kaufmann; Judith Glover; Neil Woodford; Marina Warner; Marie-France Palepou; Rachel Pike; Tyrone L Pitt; Bharat C Patel; David M Livermore Journal: J Clin Microbiol Date: 2006-10 Impact factor: 5.948
Authors: E S Go; C Urban; J Burns; B Kreiswirth; W Eisner; N Mariano; K Mosinka-Snipas; J J Rahal Journal: Lancet Date: 1994-11-12 Impact factor: 79.321
Authors: Sara E Martin; Roberta J Melander; Christopher M Brackett; Alison J Scott; Courtney E Chandler; Catherine M Nguyen; Bradley M Minrovic; Sarah E Harrill; Robert K Ernst; Colin Manoil; Christian Melander Journal: ACS Infect Dis Date: 2019-04-26 Impact factor: 5.084
Authors: Clemens Kittinger; Alexander Kirschner; Michaela Lipp; Rita Baumert; Franz Mascher; Andreas H Farnleitner; Gernot E Zarfel Journal: Int J Environ Res Public Health Date: 2017-12-30 Impact factor: 3.390
Authors: Lynette M Phee; Frank Kloprogge; Rebecca Morris; John Barrett; David W Wareham; Joseph F Standing Journal: J Antimicrob Chemother Date: 2019-04-01 Impact factor: 5.790